BMO Cuts BioMarin Target to $97 After Voxzogo Shift

BMO Capital lowered its price target on BioMarin Pharmaceutical Inc. to $97 from $98, maintaining an Outperform rating following the drugmaker's decision to discontinue development of its key treatment, Voxzogo, for Noonan syndrome, according to an Investing.com report.

The minor downward revision reflects a portfolio re-evaluation as management pivots resources away from niche indications to prioritize larger commercial opportunities in heterozygous achondroplasia and idiopathic short stature.

Pipeline Prioritization and Market Opportunities

The strategic shift involves halting a Phase 2 clinical study evaluating Voxzogo for Noonan syndrome, a genetic disorder characterized by restricted growth and distinct facial features. Rather than stemming from adverse safety findings or lackluster efficacy data, the termination was driven by financial considerations regarding the target population size.

According to the Investing.com analysis, analysts noted that the addressable patient pool for Noonan syndrome offered a comparatively modest peak-sales trajectory. Management elected to redirect capital toward broader indications such as heterozygous achondroplasia and idiopathic short stature, where the addressable patient populations and potential commercial returns are higher.

What Is Voxzogo and How Does It Work?

Voxzogo (vosoritide) is a C-type natriuretic peptide analog designed to upregulate endochondral bone growth. By binding to specific receptors, the therapy counteracts the overactive signaling pathway that inhibits bone growth in children with skeletal dysplasias.

For BioMarin, maximizing the commercial footprint of Voxzogo remains a central pillar of corporate valuation. The drug is already approved and marketed for achondroplasia, generating revenue streams that fund ongoing research and development initiatives across the company's rare disease pipeline.

Financial Context and Analyst Outlook

Despite trimming the 12-month valuation target by $1 to $97, BMO Capital's retention of the Outperform rating signals confidence in BioMarin's broader commercial execution. Analyst revisions of this magnitude are typical when pharmaceutical firms prune early-to-mid-stage clinical assets to optimize operating margins and accelerate spending in high-conviction therapeutic areas.

For equity markets, the adjustment highlights the balance between pipeline expansion and capital discipline in the biotechnology sector. By trimming less lucrative indications, BioMarin aims to streamline clinical expenses while concentrating commercial firepower on core growth drivers with multi-billion-dollar potential.